Superior virological suppression with nevirapine/zidovudine/lamivudine versus abacavir/zidovudine/lamivudine without evidence of clinical benefit to 48 weeks: a randomised comparison in patients with low CD4 counts in Africa.

From:
Department for International Development
Published
1 January 2007
Country:
Uganda
Document Type:
Research Paper
Theme:
Health
Authors:
Gilks, C., Walker, A.S., Kityo, C., Mugyenyi, P., Munderi, P., Gibb, D.M., Ssali, F., Reid, A., Kaleebu, P., Lyagoba, F., DART Trial Team

Abstract

600 HIV-infected patients in Uganda were treated with zidovudine/lamivudine plus either abacavir or nevirapine. Viral load, measured after 0, 24 and 48 weeks, was reduced in both groups but significantly more so in the nevirapine group; CD4 lymphocyte count, measured at 12-week intervals, was increased in both groups but siginificantly more so in the nevirapine group. Clinical events, although not very numerous in either group, showed a trend towards being less common in the abacavir group. Possible reasons for the inconsistent results are discussed.

Citation

14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, USA, 25-28 February 2007: Abstract 506.

Superior virological suppression with nevirapine/zidovudine/lamivudine versus abacavir/zidovudine/lamivudine without evidence of clinical benefit to 48 weeks: a randomised comparison in patients with low CD4 counts in Africa.

Published 1 January 2007
Contents